A device configured for antimicrobial, in particular bacteriostatic or bactericidal, activity, and a method for manufacturing the device. The device includes a device body having a surface. The device body is configured to anchor thermal nanoparticles supporting optical resonance, in particular localized surface plasmon resonance, at its surface. The device body includes thermal nanoparticles supporting optical resonance, in particular localized surface plasmon resonance, bonded to the surface of the device body. The thermal nanoparticles are capable of increasing their temperature by light irradiation in a wavelength range that matches with the wavelength of the optical resonance, in particular localized surface plasmon resonance, of the thermal nanoparticles. The device body also includes an antimicrobial substance that is releasable from the device body.

A syringe is to be obtained by using PTFE for a gasket main body that makes a direct contact with an injection solution and using a slidable silicone rubber at a portion that does not make contact with the injection solution.

A syringe A includes a syringe barrel 1, a gasket 10 press-fitted within the syringe barrel 1, and a plunger rod 5 mounted in the gasket 10. In the gasket 10, a concaved groove 18 is formed over the whole circumference of a slide-contact surface 11 of a main body portion 26 that is formed of a rigid plastic having a drug solution-resistant property against a drug solution 30 to be loaded in the syringe barrel 1 and that is configured to slidingly contact an inner circumferential surface 2 of the syringe barrel 1. In a slide-contact ring 19 that is to be fitted in the concaved groove 18 and that is configured to slidingly contact the syringe barrel inner circumference surface 2, a silicone oil and a spherical ultrahigh molecular weight fine powder are added to a silicone rubber base material 19c.

The present invention includes an apparatus and method of making the apparatus that biomedical apparatus comprises a device adapted for use in a biomedical application that comprises a high entropy alloy comprising at least 5 elements.

An endoprosthesis, in particular an intraluminal endoprosthesis, for example a stent, having a basic mesh composed of an at least predominantly biodegradable material, and a coating provided on the biodegradable material is proposed. For better control of the degradation the basic mesh is essentially completely covered by a coating which contains parylene, preferably at least predominantly parylene, particularly preferably parylene C or parylene N, and the basic mesh is essentially completely covered by the coating, whereby the thickness of the coating is between approximately 0.1 μm and approximately 10 μm, preferably between approximately 0.4 μm and approximately 7 μm, particularly preferably between approximately 1 μm and approximately 5 μm. Also proposed is a method for manufacturing such an endoprosthesis.

An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.

A bile duct stent and a method of manufacturing the same are disclosed. The bile duct stent having a backflow preventing means according to an embodiment of the present invention includes: a cylindrical body having a mesh structure formed by zigzagging metal wires of a shape memory alloy on a plurality of pins each disposed in a circumferential direction X and a longitudinal direction Y of a cylindrical jig; a film portion coated on cells of the metal wires of the mesh structure; and a backflow-preventing pattern film in which a hole is formed in the film portion of each cell formed at an outlet end of the cylindrical body and threads (Lasso) fixed by zigzagging to the cells of the metal wires in the circumferential direction by passing through any one hole (h) cross the outlet end one time or more to form a network structure.

The invention discloses a Zn—Ga series alloy and a preparation method and application thereof, belonging to the technical field of medical alloys. The Zn—Ga series alloy includes Zn and Ga, and Ga accounts for 0-30 wt % but not including 0. The preparation method is to mix Zn and Ga or Zn, Ga and trace elements, then to obtain a Zn—Ga series alloy by coating paint after smelting or sintering. The mechanical properties of the prepared Zn—Ga series alloy meet the requirements of the strength and toughness of medical implant materials, and it can be degraded in vivo. It has the dual characteristics of biological corrosion degradation and suitable corrosion rate to provide long-term effective mechanical support.

Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces.

A surgical staple is provided. The surgical staple includes a crown having a center portion and a foldable portion, and a pair of legs extending orthogonally from the crown and configured to puncture tissue. The crown and the pair of legs are fabricated from a biodegradable metal such that biodegradation causes the center portion to separate from the foldable portion and the pair of legs, and the foldable portion and the pair of legs are absorbable within the tissue.

Disclosed is a stent with a drug coating for preventing and treating restenosis, comprising, a stent and a drug coating covering the surface of the stent. The active ingredients in the drug coating are guaiane sesquiterpene compounds P1, P2 and P3. P1 is Zedoalactone B, P2 is a stereoisomer of P1, and P3 is Zedoarondiol. Compared with an existing sirolimus eluting stent, the present drug eluting stent can inhibit the intimal hyperplasia and the inflammatory reactions of vascular walls, and promote the endothelialization of blood vessels after the stent is implanted, and thus can prevent the long-term thrombotic complications; and has the advantages of small dosage, low cost, and no toxic side effect.